-
Mashup Score: 4RP1/Nivolumab Shows Systemic Activity in Advanced Melanoma - 2 day(s) ago
New findings reveal RP1 combined with nivolumab enhances response rates in advanced melanoma, especially with deep tumor injections, showing promising safety and efficacy.
Source: www.targetedonc.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
Compared with nivolumab alone, nivolumab/relatlimab did not improve RFS in patients with resected stage III to IV melanoma.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Nivolumab plus relatlimab failed to improve recurrence-free survival vs nivolumab alone in patients with completely resected stage III to IV melanoma. #melsm #ASCO25 | @ASCO https://t.co/H0hZ19JXPW
-
-
Mashup Score: 0
The combination elicited a clinical benefit rate of 63.0% and an overall response rate of 22.2% in anti–PD-L1–refractory melanoma with melanoma brain metastases.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet-
Nivolumab plus relatlimab demonstrated intracranial activity in patients with anti–PD-(L)1 refractory melanoma who have melanoma brain metastases, though more confirmatory data is needed. #melsm #ASCO25 | @ASCO https://t.co/8zFmQ3q41X
-
-
Mashup Score: 1
Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma. #melsm #ASCO25 | @ASCO https://t.co/FD82XjWrid
-
An analysis of the phase 2 IGNYTE trial showed that the effectiveness of the oncolytic immunotherapy RP1 + nivolumab in advanced melanoma patients who had previously not responded to a PD-1 inhibitor. #melsm #ASCO25 @Gino_K_In_USC https://t.co/W6j27CgdSQ